177 related articles for article (PubMed ID: 34181165)
1. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease.
Parekh R; Zhang X; Ungaro RC; Brenner EJ; Agrawal M; Colombel JF; Kappelman MD
Dig Dis Sci; 2022 Apr; 67(4):1271-1277. PubMed ID: 34181165
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.
Ludvigsson JF; Axelrad J; Halfvarson J; Khalili H; Larsson E; Lochhead P; Roelstraete B; Simon TG; Söderling J; Olén O
United European Gastroenterol J; 2021 Mar; 9(2):177-192. PubMed ID: 33704918
[TBL] [Abstract][Full Text] [Related]
5. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
Derikx LAAP; Lantinga MA; de Jong DJ; van Dop WA; Creemers RH; Römkens TEH; Jansen JM; Mahmmod N; West RL; Tan ACITL; Bodelier AGL; Gorter MHP; Boekema PJ; Halet ERC; Horjus CS; van Dijk MA; Hirdes MMC; Epping Stippel LSM; Jharap B; Lutgens MWMD; Russel MG; Gilissen LPL; Nauta S; van Bodegraven AA; Hoentjen F
J Crohns Colitis; 2021 Apr; 15(4):529-539. PubMed ID: 33079178
[TBL] [Abstract][Full Text] [Related]
7. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
Roy S; Sheikh SZ; Furey TS
Sci Rep; 2021 Aug; 11(1):16522. PubMed ID: 34389789
[TBL] [Abstract][Full Text] [Related]
8. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
[TBL] [Abstract][Full Text] [Related]
9. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
10. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients.
Azzam NA; Aljebreen A; Almuhareb A; Almadi MA
Saudi J Gastroenterol; 2020; 26(5):256-262. PubMed ID: 32415045
[TBL] [Abstract][Full Text] [Related]
11. Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
Richter V; Bermont A; Cohen DL; Broide E; Shirin H
Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):267-273. PubMed ID: 34191758
[TBL] [Abstract][Full Text] [Related]
12. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
[TBL] [Abstract][Full Text] [Related]
14. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Singh AK; Jena A; Kumar-M P; Sharma V; Sebastian S
United European Gastroenterol J; 2021 Mar; 9(2):159-176. PubMed ID: 33210980
[TBL] [Abstract][Full Text] [Related]
15. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
[TBL] [Abstract][Full Text] [Related]
16. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey.
Nakase H; Wagatsuma K; Nojima M; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Takeuchi K; Tamura S; Kinjo F; Ueno N; Naganuma M; Watanabe K; Moroi R; Nishimata N; Motoya S; Kurahara K; Takahashi S; Maemoto A; Sakuraba H; Saruta M; Tominaga K; Hisabe T; Tanaka H; Terai S; Hiraoka S; Takedomi H; Narimatsu K; Endo K; Nakamura M; Hisamatsu T
J Gastroenterol; 2023 Mar; 58(3):205-216. PubMed ID: 36607399
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
18. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.
Abdulla M; Mohammed N; AlQamish J; Mosli M
Sci Rep; 2022 Dec; 12(1):21333. PubMed ID: 36494448
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
